Get updates from ProMIS Neurosciences, Inc. (PMN) Press Releases via email, on your phone or read them on follow.it on your own custom news page.
You can filter the news from ProMIS Neurosciences, Inc. (PMN) Press Releases that get delivered to you using tags or topics or you can opt for all of them. Unsubscription is also very simple.
See the latest news from ProMIS Neurosciences, Inc. (PMN) Press Releases below.
Site title: ProMIS Neurosciences, Inc. (PMN)
Is this your feed? Claim it!
PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in early 2027
PMN310 continues to demonstrate a favorable safety profile, with no treatment-related serious adver...
Cambridge, Massachusetts, March 18, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that it will present two scientific posters at the Alzheimer’s & Parkinson’s Diseases Conferenc...
Cambridge, Massachusetts, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced the company will be participating in a fireside chat and investor one-on-one meetings at the Guggenheim...
Extends cash runway into 2028
Proceeds expected to enable completion of ProMIS’ landmark Phase 1b AD study and support execution of key clinical milestones
Blinded 6-month top-line data expected mid-2026; 12-month top-line data expected toward end of 2026
CAMBRIDGE, M...